Abstract
We are in the midst of a technological revolution that is providing new insights into human biology and cancer. In this era of big data, we are amassing large amounts of information that is transforming how we approach cancer treatment and prevention. Enactment of the Cancer Moonshot within the 21st Century Cures Act in the USA arrived at a propitious moment in the advancement of knowledge, providing nearly US$2 billion of funding for cancer research and precision medicine. In 2016, the Blue Ribbon Panel (BRP) set out a roadmap of recommendations designed to exploit new advances in cancer diagnosis, prevention, and treatment. Those recommendations provided a high-level view of how to accelerate the conversion of new scientific discoveries into effective treatments and prevention for cancer. The US National Cancer Institute is already implementing some of those recommendations. As experts in the priority areas identified by the BRP, we bolster those recommendations to implement this important scientific roadmap. In this Commission, we examine the BRP recommendations in greater detail and expand the discussion to include additional priority areas, including surgical oncology, radiation oncology, imaging, health systems and health disparities, regulation and financing, population science, and oncopolicy. We prioritise areas of research in the USA that we believe would accelerate efforts to benefit patients with cancer. Finally, we hope the recommendations in this report will facilitate new international collaborations to further enhance global efforts in cancer control.
| Original language | English (US) |
|---|---|
| Pages (from-to) | e653-e706 |
| Journal | The Lancet. Oncology |
| Volume | 18 |
| Issue number | 11 |
| DOIs | |
| State | Published - Nov 1 2017 |
Fingerprint
ASJC Scopus subject areas
- Oncology
Cite this
Future cancer research priorities in the USA : a Lancet Oncology Commission. / Jaffee, Elizabeth M.; Dang, Chi Van; Agus, David B.; Alexander, Brian M.; Anderson, Kenneth C.; Ashworth, Alan; Barker, Anna; Bastani, Roshan; Bhatia, Sangeeta; Bluestone, Jeffrey A.; Brawley, Otis; Butte, Atul J.; Coit, Daniel G.; Davidson, Nancy E.; Davis, Mark; DePinho, Ronald A.; Diasio, Robert B.; Draetta, Giulio; Frazier, A. Lindsay; Futreal, Andrew; Gambhir, Sam S.; Ganz, Patricia A.; Garraway, Levi; Gerson, Stanton; Gupta, Sumit; Heath, James; Hoffman, Ruth I.; Hudis, Cliff; Hughes-Halbert, Chanita; Ibrahim, Ramy; Jadvar, Hossein; Kavanagh, Brian; Kittles, Rick; Le, Quynh Thu; Lippman, Scott M.; Mankoff, David; Mardis, Elaine R.; Mayer, Deborah K.; McMasters, Kelly; Meropol, Neal J.; Mitchell, Beverly; Naredi, Peter; Ornish, Dean; Pawlik, Timothy M.; Peppercorn, Jeffrey; Pomper, Martin G.; Raghavan, Derek; Ritchie, Christine; Schwarz, Sally W.; Sullivan, Richard; Wahl, Richard; Wolchok, Jedd D.; Wong, Sandra L.; Yung, Alfred.
In: The Lancet. Oncology, Vol. 18, No. 11, 01.11.2017, p. e653-e706.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Future cancer research priorities in the USA
T2 - a Lancet Oncology Commission
AU - Jaffee, Elizabeth M.
AU - Dang, Chi Van
AU - Agus, David B.
AU - Alexander, Brian M.
AU - Anderson, Kenneth C.
AU - Ashworth, Alan
AU - Barker, Anna
AU - Bastani, Roshan
AU - Bhatia, Sangeeta
AU - Bluestone, Jeffrey A.
AU - Brawley, Otis
AU - Butte, Atul J.
AU - Coit, Daniel G.
AU - Davidson, Nancy E.
AU - Davis, Mark
AU - DePinho, Ronald A.
AU - Diasio, Robert B.
AU - Draetta, Giulio
AU - Frazier, A. Lindsay
AU - Futreal, Andrew
AU - Gambhir, Sam S.
AU - Ganz, Patricia A.
AU - Garraway, Levi
AU - Gerson, Stanton
AU - Gupta, Sumit
AU - Heath, James
AU - Hoffman, Ruth I.
AU - Hudis, Cliff
AU - Hughes-Halbert, Chanita
AU - Ibrahim, Ramy
AU - Jadvar, Hossein
AU - Kavanagh, Brian
AU - Kittles, Rick
AU - Le, Quynh Thu
AU - Lippman, Scott M.
AU - Mankoff, David
AU - Mardis, Elaine R.
AU - Mayer, Deborah K.
AU - McMasters, Kelly
AU - Meropol, Neal J.
AU - Mitchell, Beverly
AU - Naredi, Peter
AU - Ornish, Dean
AU - Pawlik, Timothy M.
AU - Peppercorn, Jeffrey
AU - Pomper, Martin G.
AU - Raghavan, Derek
AU - Ritchie, Christine
AU - Schwarz, Sally W.
AU - Sullivan, Richard
AU - Wahl, Richard
AU - Wolchok, Jedd D.
AU - Wong, Sandra L.
AU - Yung, Alfred
PY - 2017/11/1
Y1 - 2017/11/1
N2 - We are in the midst of a technological revolution that is providing new insights into human biology and cancer. In this era of big data, we are amassing large amounts of information that is transforming how we approach cancer treatment and prevention. Enactment of the Cancer Moonshot within the 21st Century Cures Act in the USA arrived at a propitious moment in the advancement of knowledge, providing nearly US$2 billion of funding for cancer research and precision medicine. In 2016, the Blue Ribbon Panel (BRP) set out a roadmap of recommendations designed to exploit new advances in cancer diagnosis, prevention, and treatment. Those recommendations provided a high-level view of how to accelerate the conversion of new scientific discoveries into effective treatments and prevention for cancer. The US National Cancer Institute is already implementing some of those recommendations. As experts in the priority areas identified by the BRP, we bolster those recommendations to implement this important scientific roadmap. In this Commission, we examine the BRP recommendations in greater detail and expand the discussion to include additional priority areas, including surgical oncology, radiation oncology, imaging, health systems and health disparities, regulation and financing, population science, and oncopolicy. We prioritise areas of research in the USA that we believe would accelerate efforts to benefit patients with cancer. Finally, we hope the recommendations in this report will facilitate new international collaborations to further enhance global efforts in cancer control.
AB - We are in the midst of a technological revolution that is providing new insights into human biology and cancer. In this era of big data, we are amassing large amounts of information that is transforming how we approach cancer treatment and prevention. Enactment of the Cancer Moonshot within the 21st Century Cures Act in the USA arrived at a propitious moment in the advancement of knowledge, providing nearly US$2 billion of funding for cancer research and precision medicine. In 2016, the Blue Ribbon Panel (BRP) set out a roadmap of recommendations designed to exploit new advances in cancer diagnosis, prevention, and treatment. Those recommendations provided a high-level view of how to accelerate the conversion of new scientific discoveries into effective treatments and prevention for cancer. The US National Cancer Institute is already implementing some of those recommendations. As experts in the priority areas identified by the BRP, we bolster those recommendations to implement this important scientific roadmap. In this Commission, we examine the BRP recommendations in greater detail and expand the discussion to include additional priority areas, including surgical oncology, radiation oncology, imaging, health systems and health disparities, regulation and financing, population science, and oncopolicy. We prioritise areas of research in the USA that we believe would accelerate efforts to benefit patients with cancer. Finally, we hope the recommendations in this report will facilitate new international collaborations to further enhance global efforts in cancer control.
UR - http://www.scopus.com/inward/record.url?scp=85032672086&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85032672086&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(17)30698-8
DO - 10.1016/S1470-2045(17)30698-8
M3 - Review article
VL - 18
SP - e653-e706
JO - The Lancet Oncology
JF - The Lancet Oncology
SN - 1470-2045
IS - 11
ER -